Why Farbe Firma is the Top Manufacturer of Atropine Sulphate Injection
- Maulik Sudani
- May 22
- 6 min read
Last Updated: May 22, 2026
TL;DR: Atropine Sulphate Injection — atropine sulphate, a tropane-alkaloid antimuscarinic agent supplied as a clear sterile aqueous solution in small-volume ampoules — is the emergency-medicine staple clinicians rely on to treat symptomatic bradycardia, to dry secretions before anaesthesia, and, critically, as the first-line antidote to organophosphate, carbamate and nerve-agent poisoning. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Atropine Sulphate Injection at our Gujarat, India facility and supplies it to hospital tenders, crash-cart programmes, distributors and brand owners in 30+ countries.
Key Takeaways
Drug class: Antimuscarinic (anticholinergic) tropane alkaloid — a competitive muscarinic acetylcholine-receptor antagonist used for symptomatic bradycardia, as an antisialagogue premedication, and as the antidote of choice for cholinesterase-inhibitor (organophosphate and carbamate) poisoning. A WHO Essential Medicine and a universal crash-cart item.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule filling lines with nitrogen purging and tight pH control, and validated terminal moist-heat sterilisation with full container-closure integrity verification.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets.
End-to-end CMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Atropine Sulphate Injection Demands a Premium Manufacturer
Atropine Sulphate Injection sits on every resuscitation trolley for a reason: when a patient's heart rate falls dangerously low, or when a cholinesterase-inhibitor poisoning floods the body with acetylcholine, atropine is the drug that has to work immediately and exactly as labelled. As a competitive antagonist at muscarinic acetylcholine receptors, atropine blocks excessive parasympathetic activity — lifting the heart rate in symptomatic bradycardia, drying salivary and bronchial secretions before anaesthesia, and reversing the muscarinic crisis caused by organophosphate pesticides, carbamates and nerve agents. In agricultural regions where pesticide poisoning is a frequent emergency, a dependable supply of Atropine Sulphate Injection is not a convenience; it is a public-health necessity.
That clinical role places unusual demands on the manufacturer. Atropine is a potent, low-dose alkaloid presented in small fill volumes — commonly 0.6 mg/mL and 1 mg/mL in 1 mL ampoules — so every ampoule must deliver an accurate dose with tight content uniformity. The molecule is also an ester, and esters hydrolyse: atropine slowly breaks down to tropic acid and tropine, and that reaction accelerates at alkaline pH and elevated temperature. Producing it correctly means holding the solution within a narrow acidic stability window, purging dissolved oxygen, protecting product from light, and validating the terminal sterilisation cycle against a defined degradation budget. Choosing an Atropine Sulphate Injection manufacturer that treats pH control, dose uniformity and ampoule integrity as core engineering disciplines — not afterthoughts — is what keeps a life-saving supply chain dependable.
What Sets a World-Class Atropine Sulphate Injection Manufacturer Apart
A world-class manufacturer of Atropine Sulphate Injection invests in three areas competitors often underinvest in: precision low-dose formulation, hydrolysis-controlled processing, and a stability programme that mirrors real-world distribution. Precision low-dose formulation goes beyond simple compounding — it means validated dissolution of a milligram-scale active into large solution batches, in-process assay at multiple points, controlled fill-weight checks across the run, and content-uniformity verification so that the first ampoule and the last ampoule of a batch carry the same accurate dose. For a drug titrated in fractions of a milligram during a cardiac emergency, that consistency is non-negotiable.
Hydrolysis-controlled processing matters because atropine's ester bond is its weak point. World-class plants prepare the bulk solution under nitrogen blanket to limit oxidation, adjust and verify pH within the narrow acidic band where atropine is most stable, minimise the time the bulk spends warm, and validate the moist-heat sterilisation cycle so the lethality delivered to microorganisms does not come at the cost of unacceptable drug degradation. All of this is documented cleanly for audit, supported by electronic batch records that lock deviations the moment they occur, and reinforced by light-protected staging and 100% ampoule leak and integrity inspection from filling through final packaging.
Quality Systems Behind Every Atropine Sulphate Injection
Every Farbe Firma Atropine Sulphate Injection batch is released only after a full stack of quality checks: identity and assay by validated stability-indicating HPLC against USP, BP, IP or EP reference standards, related-substances profiling to confirm tropic acid and other hydrolysis products stay within monograph limits, pH, particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and content-uniformity testing appropriate to a low-dose parenteral. Certificates of analysis are issued with full traceability back to API lot, excipient lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal moist-heat cycles with load mapping, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — so we can assure customers the Atropine Sulphate Injection they buy today will still meet specification when it reaches the patient months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Atropine Sulphate Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across emergency-medicine, anaesthesia, analgesic, anti-emetic and critical-care categories. For Atropine Sulphate Injection specifically, we supply the 0.6 mg/mL and 1 mg/mL ampoule presentations as standard, with custom strengths, fill volumes and pack configurations — including high-dose formats for organophosphate-poisoning protocols — available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from hospital pharmacy supply to full national tender procurement. We prepare full eCTD and ACTD modules, drug master files, ICH Q1A stability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Atropine Sulphate Injection on a tight deadline — and emergency-medicine stock often is urgent — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit responds to technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through formulation, pH control, sterilisation strategy, container-closure and stability choices in real detail. For an emergency parenteral where dose accuracy and sterility decide patient outcomes, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Atropine Sulphate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Atropine Sulphate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling lines, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Atropine Sulphate Injection do you supply?
Our standard presentations are atropine sulphate 0.6 mg/mL and 1 mg/mL as a clear sterile solution in 1 mL single-dose ampoules for intravenous, intramuscular or subcutaneous use. Custom strengths, fill volumes, vial formats and high-dose packs for organophosphate-poisoning protocols are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Atropine Sulphate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages (long-term and accelerated), and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma protect Atropine Sulphate Injection from hydrolysis and degradation?
Atropine is an ester and hydrolyses faster at alkaline pH and high temperature, so the bulk solution is prepared under nitrogen blanket, the pH is adjusted and verified within atropine's narrow acidic stability window, and the terminal moist-heat sterilisation cycle is validated against a defined degradation budget. Hydrolysis products such as tropic acid are monitored on every batch by validated stability-indicating HPLC against monograph limits.
What is the minimum order quantity for Atropine Sulphate Injection contract manufacturing?
MOQs vary by strength, label complexity and dossier requirements. For the standard 0.6 mg/mL and 1 mg/mL ampoule presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments